Skip to main content

Advertisement

SpringerLink
Log in

Prevention of cardiovascular disease in women

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Appropriate screening and lifestyle modification are the foundations of effective cardiovascular disease (CVD) prevention in women. All adult women should undergo a cardiovascular risk assessment, including family history, smoking, diet, and exercise assessments, and measurement of fasting lipid profile, waist and hip dimensions, and blood pressure. Women should be advised of their 10-year estimated risk of developing a cardiovascular event using the Framingham risk calculator as recommended by the National Cholesterol Education Program. Based on the level of risk, women should receive counseling on dietary modification, physical activity, weight loss, and the need for pharmacologic intervention for blood pressure, lipid, and diabetes management. In addition, women who are overweight, have a history of gestational diabetes, or family history of diabetes should have a fasting glucose measured. Women who smoke should receive advice, encouragement, and assistance for smoking cessation. Postmenopausal hormone therapy should not be considered a treatment option for primary or secondary prevention of CVD. Women and their families should be advised of the possible signs of CVD and the need to seek immediate medical attention in the event of prolonged, new, or severe symptoms. Women with coronary artery disease especially need close attention to their risk factor levels and should receive intensive intervention to achieve optimal control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Heart Association: American Heart Association 2003 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association: 2002.

    Google Scholar 

  2. Mosca L, Manson JE, Sutherland SE, et al.: Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association Writing Group. Circulation 1997, 96:2468–2482.

    PubMed  CAS  Google Scholar 

  3. American Heart Association: Women and Heart Disease: a study tracking women’s awareness of and attitudes toward heart disease and stroke. 2000. http://www.americanheart.org/presenter.jhtml?identifier= 10382. Accessed January 31, 2003.

  4. Robertson RM: Women and cardiovascular disease: the risks of misperception and the need for action. Circulation 2001, 103:2318–2320.

    PubMed  CAS  Google Scholar 

  5. National Heart Lung and Blood Institute: Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) full report: manuscript version. http://www.nhlbi.nih.gov/guidelines/cholesterol/ atp3_rpt.htm. Accessed January 31, 2003. An important update in the ongoing effort to improve cholesterol screening and management. The availability of online and downloadable tools aids in the implementation of the latest management recommendations.

  6. Pearson TA, Blair SN, Daniels SR, et al.: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002, 106:388–391. Provides concise guidelines for screening and intervention of cardiac risk factors.

    Article  PubMed  Google Scholar 

  7. Wilson PW, D’Agostino B, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847.

    PubMed  CAS  Google Scholar 

  8. Grundy SM, Pasternak R, Greenland P, et al.: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999, 100:1481–1492.

    PubMed  CAS  Google Scholar 

  9. National Cholesterol Education Program: Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood cholesterol in Adults (ATP III), 10-year risk calculator. http:// www.nhlbi.nih.gov/guidelines/cholesterol/index.htm. Accessed January 31, 2003.

  10. Eckel RJ, Krauss RM: American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998, 97:2099–2100.

    PubMed  CAS  Google Scholar 

  11. Krauss R, Eckel R, Howard B, et al.: AHA dietary guidelines-Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000, 102:2284–2299.

    PubMed  CAS  Google Scholar 

  12. Hu FB, Bronner L, Willett WC, et al.: Fish and omega-3 fatty acid intake and risk of coronary heart disease in women JAMA 2002, 287:1815–1821.

    Article  PubMed  CAS  Google Scholar 

  13. Knekt P, Reunanen A, Jarvinen R, et al.: Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994, 139:1180–1189.

    PubMed  CAS  Google Scholar 

  14. Manson JE, Greenland P, LaCroix AZ, et al.: Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 2002, 347:716–725. An analysis of over 70,000 women revealed that increasing quintiles of energy expenditure yielded graded reductions in the relative risk of coronary events over 5.9 years of follow-up. Even walking resulted in lower risk than no reported exertion. Walking for 2.5 h/wk reduced risk by 30%. For those who exercised vigorously for over 100 min/wk, risk was reduced by over 60%.

    Article  PubMed  Google Scholar 

  15. Pate RR, Pratt M, Blair SN, et al.: Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995, 273:402–407.

    Article  PubMed  CAS  Google Scholar 

  16. Greendale GA, Bodin-Dunn L, Ingles S, et al.: Leisure, home and occupational physical activity and cardiovascular risk factors in postmenopausal women: the Postmenopausal Estrogens/Progestins Intervention (PEPI) study. Arch Intern Med 1996, 156:418–424.

    Article  PubMed  CAS  Google Scholar 

  17. Mosca L, Grundy SM, Judelson D, et al.: AHA/ACC Scientific Statement: Consensus Panel Statement. Guide to preventive cardiology for women. Circulation 1999, 99:2480–2484. Covers the most important factors for cardiac risk reduction for women. The hormone statements have been updated (see references [50] and [51]).

    PubMed  CAS  Google Scholar 

  18. Rich-Edwards JW, Manson JE, Henekens CH, Buring JE: The primary prevention of coronary heart disease in women. N Engl J Med 1995, 332:1758–1766.

    Article  PubMed  CAS  Google Scholar 

  19. Wenger NK: Addressing coronary heart disease risk in women. Cleve Clin J Med 1998, 65:464–469.

    PubMed  CAS  Google Scholar 

  20. Mosca L, Manson JE, Sutherland SE, et al.: Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation 1997, 96:2468–2482.

    PubMed  CAS  Google Scholar 

  21. Kawachi I, Colditz GA, Stampfer MJ, et al.: Smoking cessation in relation to total mortality rates in women: a prospective cohort study. Ann Intern Med 1993, 119:992–1000.

    PubMed  CAS  Google Scholar 

  22. Stansfeld SA: Psychological distress as a risk factor for coronary heart disease in the Whitehall II Study. Int J Epidemiol 2002, 31:248–255.

    Article  PubMed  Google Scholar 

  23. Sempos CT, Cleeman JI, Carroll MD, et al.: Prevalence of high blood cholesterol among U. S. adults: an update based on guidelines from the Second Report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993, 269:3009–3014.

    Article  PubMed  CAS  Google Scholar 

  24. Jacobs DR, Mebane IL, Bangdiwala SI, et al.: High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990, 131:32–47.

    PubMed  Google Scholar 

  25. Castelli WP: Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992, 70:3H-9H.

    Article  PubMed  CAS  Google Scholar 

  26. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [no authors listed]. Lancet 1994, 344:1383–389.

  27. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. AFCAPS/TexCAPS Research Group. JAMA 1998, 279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  28. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.

  29. Hodis HN, Mack WJ, Lobo R: Anti-atherosclerosis interventions in women. Am J Cardiol 2002, 90(1A):17F-21F.

    Article  PubMed  CAS  Google Scholar 

  30. Miettinen TA, Pyorala K, Olsson AG, et al.: Cholesterollowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997, 96:4211–4218.

    PubMed  CAS  Google Scholar 

  31. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure [no authors listed]. Arch Intern Med 1997, 157:2413–2446.

  32. National High Blood Pressure Education Working Group Report on hypertension in the elderly. National High Blood Pressure Education Program Working Group [no authors listed]. Hypertension 1994, 23:275–285.

  33. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group [no authors listed]. N Engl J Med 2002;346:393–403. A landmark study demonstrating that counseling and coaching to change diet patterns, improve weight, and participate in 150 minutes of exercise per week could prevent the development of type 2 diabetes in high-risk men and women. Lifestyle changes were more effective in preventing diabetes than the use of metformin.

  34. Wyngard DL, Barrett-Connor E: Heart disease and diabetes. In Diabetes in America, edn 2. NIDDK, NIH Pub. No. 95-1468. Bethesda, MD: National Institutes of Health; 1995:429–448. http://www.niddk.nih.gov/health/diabetes/dia/chpt19.pdf. Accessed January 31, 2003.

    Google Scholar 

  35. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [no authors listed]. Diabetes Care 1997, 20:1183–1197.

  36. Grundy SM, Howard B, Smith S, et al.: Prevention Conference VI: Diabetes and Cardiovascular Disease. Executive Summary. Circulation 2002, 105:2231–2239.

    Article  PubMed  Google Scholar 

  37. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration [no authors listed]. BMJ 1994, 308:81–106.

  38. Patr NC, Coller BD, Alen JE, et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2000, 119(suppl 3):9S-63S.

    Google Scholar 

  39. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. U. S. Preventive Services Task Force [no authors listed]. Ann Intern Med 2002, 136:157–160.

  40. Egger M, Schneider M, Davey G: Spurious precision? Meta-analysis of observational studies. BMJ 1998, 316:140–144.

    PubMed  CAS  Google Scholar 

  41. Yusuf S, Dagenais G, Pogue J, et al.: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:154–160.

    Article  PubMed  CAS  Google Scholar 

  42. Glosdsland IF, Crook D, Simpson R, et al.: The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990, 323:1375–1381.

    Article  Google Scholar 

  43. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception [no authors listed]. Lancet 1997, 349:1202–1209.

  44. Stampfer MJ, Coldit GA, Willett WC, et al.: Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991, 325:756–762.

    Article  PubMed  CAS  Google Scholar 

  45. Mosca L, Collins P, Herrington DM, et al.: Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001, 104:499–503.

    PubMed  CAS  Google Scholar 

  46. Bush TL: Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J 1996, 17(suppl):9–14.

    PubMed  CAS  Google Scholar 

  47. Rackley CE: Estrogen and coronary artery disease in postmenopausal women. Am J Med 1995, 99:117–118.

    Article  PubMed  CAS  Google Scholar 

  48. Manson JE: Postmenopausal hormone therapy and atherosclerotic disease. Am Heart J 1994, 128:1337–1343.

    Article  PubMed  CAS  Google Scholar 

  49. Grodstein F, Manson JE, Colditz GA, et al.: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000, 133:933–941.

    PubMed  CAS  Google Scholar 

  50. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative Randomized Controlled Trial. Writing Group for the Women’s Health Initiative Investigators [no authors listed]. JAMA 2002, 288:321–333. Newsbreaking report of the large randomized estrogen plus progestin study of 50-to 79-year-old women, most without coronary disease at the time of enrollment. The study was stopped early because of increased risks and lack of overall benefit for combination HRT.

  51. American Heart Association: Media Advisory 07/09/02, American Heart Association President Robert Bonow MD responds to new findings from the Women’s Health Initiative Trial. http://www.americanheart.org/ presenter.jhtml?identifier=3003700. Accessed September 10, 2002.

  52. Graham IM, Daly LE, Refsum HM, et al.: Plasma homocysteine as a risk factor for cardiovascular disease: the European Concerted Action project. JAMA 1997, 277:1775–1781.

    Article  PubMed  CAS  Google Scholar 

  53. Thompson GR, Naoumova RP: Novel lipid-regulating drugs. Expert Opin Investig Drugs 2000, 9:2619–2628.

    Article  PubMed  CAS  Google Scholar 

  54. Chowdhury JR, Grossman M, Gupta S, et al.: Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991, 254:1802–1805.

    Article  PubMed  CAS  Google Scholar 

  55. Grossman M, Rader DJ, Muller DW, et al.: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia. Nat Med 1995, 1:1148–1154.

    Article  PubMed  CAS  Google Scholar 

  56. Psaty BM, Smith NL, Lemaitre RN, et al.: Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001, 285:906–913.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, 1600 SW Archer Road, PO Box 100277, 32610-0277, Gainesville, FL, USA

    Omer L. Shedd MD & Marian C. Limacher MD

Authors
  1. Omer L. Shedd MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marian C. Limacher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shedd, O.L., Limacher, M.C. Prevention of cardiovascular disease in women. Curr Treat Options Cardio Med 5, 287–298 (2003). https://doi.org/10.1007/s11936-003-0028-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-003-0028-6

Keywords

Search

Navigation